Chief Financial Officer · Solid Biosciences Inc. (SLDB)

Kevin Tan

FY2023 is the first fiscal year CompBrief holds for Kevin Tan as a named executive officer of Solid Biosciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,346,305

Salary $416,146Stock awards $270,000Bonus $170,000

2nd of 4 named executive officers at Solid Biosciences by FY2023 total.

4 named officers on file for Solid Biosciences, FY2023

Kevin Tan’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Solid Biosciences’s whole pay program stands against its peers

  • Solid Biosciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SLDB→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Kevin Tan’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kevin Tan compensation by year

Solid Biosciences Summary Compensation Table · the one fiscal year held
In US dollars, as Solid Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$416,146
Bonus$170,000
Stock awards$270,000
Option awards$478,279
Non-equity incentive$0
Pension and deferred compensation$0
All other$11,880
Total$1,346,305

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Solid Biosciences Inc. DEF 14A filed April 26, 2024, accession 0001193125-24-118079, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Solid Biosciences Inc. filed document, accession 0001193125-24-118079. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU45,000$276,300—
Option90,000—$6.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Solid Biosciences Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

24 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-18Sale10b5-15,404$5.8299,422
2026-02-13Exercise or conversion derivative10b5-110,625$0.0021,250
2026-02-13Exercise or conversion10b5-110,625—104,826
2026-02-04Sale10b5-114,783$6.4494,201
2026-02-02Sale10b5-126,837$6.44108,984
2026-01-31Exercise or conversion derivative10b5-133,075$0.0099,225
2026-01-31Exercise or conversion10b5-133,075—135,821
2026-01-29Grant or award derivative10b5-193,500$0.0093,500

The 8 most recent of 24 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Solid Biosciences’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Carl MorrisFormer Chief Scientific Officer, Neuromuscular (8)$1,559,449
Kevin Tan · this pageChief Financial Officer$1,346,305
Alexander CumboPresident and Chief Executive Officer$918,630
David Tyronne HowtonChief Operating Officer, General Counsel and Secretary$648,880

The full Solid Biosciences compensation record

free company brief

This page is one person within Solid Biosciences's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Solid Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kevin Tan's compensation dossier · One-time report. No refunds.